MX2019008434A - Muteínas de lipocalina con afinidad de unión por lag-3. - Google Patents
Muteínas de lipocalina con afinidad de unión por lag-3.Info
- Publication number
- MX2019008434A MX2019008434A MX2019008434A MX2019008434A MX2019008434A MX 2019008434 A MX2019008434 A MX 2019008434A MX 2019008434 A MX2019008434 A MX 2019008434A MX 2019008434 A MX2019008434 A MX 2019008434A MX 2019008434 A MX2019008434 A MX 2019008434A
- Authority
- MX
- Mexico
- Prior art keywords
- lipocalin muteins
- lag
- present disclosure
- human
- muteins
- Prior art date
Links
- 102000019298 Lipocalin Human genes 0.000 title abstract 8
- 108050006654 Lipocalin Proteins 0.000 title abstract 8
- 101100510617 Caenorhabditis elegans sel-8 gene Proteins 0.000 title 1
- 102000017578 LAG3 Human genes 0.000 abstract 3
- 101150030213 Lag3 gene Proteins 0.000 abstract 3
- 102000043131 MHC class II family Human genes 0.000 abstract 2
- 108091054438 MHC class II family Proteins 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 150000007523 nucleic acids Chemical class 0.000 abstract 2
- 102000039446 nucleic acids Human genes 0.000 abstract 2
- 108020004707 nucleic acids Proteins 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 208000035473 Communicable disease Diseases 0.000 abstract 1
- 101000946124 Homo sapiens Lipocalin-1 Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2318/00—Antibody mimetics or scaffolds
- C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Rheumatology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17151945 | 2017-01-18 | ||
| PCT/EP2018/051139 WO2018134274A1 (en) | 2017-01-18 | 2018-01-18 | Lipocalin muteins with binding affinity for lag-3 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019008434A true MX2019008434A (es) | 2019-11-11 |
Family
ID=57860697
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019008434A MX2019008434A (es) | 2017-01-18 | 2018-01-18 | Muteínas de lipocalina con afinidad de unión por lag-3. |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11168119B2 (enExample) |
| EP (1) | EP3571219A1 (enExample) |
| JP (1) | JP7225116B2 (enExample) |
| KR (1) | KR20190104409A (enExample) |
| CN (1) | CN110402252A (enExample) |
| AU (1) | AU2018209178B2 (enExample) |
| BR (1) | BR112019014691A2 (enExample) |
| CA (1) | CA3050194A1 (enExample) |
| MX (1) | MX2019008434A (enExample) |
| RU (1) | RU2019122482A (enExample) |
| SG (1) | SG11201906509WA (enExample) |
| WO (1) | WO2018134274A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108348573A (zh) | 2015-07-15 | 2018-07-31 | 皮里斯制药有限公司 | Lag-3特异性的新型蛋白 |
| MX2019008434A (es) | 2017-01-18 | 2019-11-11 | Pieris Pharmaceuticals Gmbh | Muteínas de lipocalina con afinidad de unión por lag-3. |
| CN113939307A (zh) * | 2019-03-29 | 2022-01-14 | 皮里斯制药有限公司 | 脂质运载蛋白突变蛋白的吸入施用 |
| CN116249709A (zh) | 2020-06-05 | 2023-06-09 | 皮里斯制药有限公司 | 靶向4-1bb的多聚体免疫调节剂 |
| EP4320141A1 (en) * | 2021-04-08 | 2024-02-14 | Pieris Pharmaceuticals GmbH | Novel lipocalin muteins specific for connective tissue growth factor (ctgf) |
| CN113480667B (zh) * | 2021-08-17 | 2023-03-28 | 长春萤火虫生物科技有限公司 | 一种人粒细胞集落刺激因子突变体重组融合蛋白及其制备方法和应用 |
| CN113754743B (zh) * | 2021-10-12 | 2024-02-02 | 成都齐碳科技有限公司 | 孔蛋白单体的突变体、蛋白孔及其应用 |
| WO2023118497A1 (en) | 2021-12-22 | 2023-06-29 | Pieris Pharmaceuticals Gmbh | Novel il-18 variants |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH01215289A (ja) | 1988-02-22 | 1989-08-29 | Toa Nenryo Kogyo Kk | 遺伝子組換えによる正常ヒト血清アルブミンａの製造方法 |
| FR2649991B2 (fr) | 1988-08-05 | 1994-03-04 | Rhone Poulenc Sante | Utilisation de derives stables du plasmide pkd1 pour l'expression et la secretion de proteines heterologues dans les levures du genre kluyveromyces |
| US5728553A (en) | 1992-09-23 | 1998-03-17 | Delta Biotechnology Limited | High purity albumin and method of producing |
| US5908621A (en) | 1995-11-02 | 1999-06-01 | Schering Corporation | Polyethylene glycol modified interferon therapy |
| US6620413B1 (en) | 1995-12-27 | 2003-09-16 | Genentech, Inc. | OB protein-polymer chimeras |
| DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
| GB9722131D0 (en) | 1997-10-20 | 1997-12-17 | Medical Res Council | Method |
| CA2233725A1 (en) | 1998-03-31 | 1999-09-30 | Hemosol Inc. | Hemoglobin-hydroxyethyl starch complexes |
| PL192364B1 (pl) | 1998-06-08 | 2006-10-31 | Hoffmann La Roche | Zastosowanie koniugatu PEG-IFN-α 2A w połączeniu z rybawiryną |
| US6403564B1 (en) | 1998-10-16 | 2002-06-11 | Schering Corporation | Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection |
| GB2379448B (en) | 1999-06-02 | 2004-03-31 | Abb Research Ltd | Coating composition for high temperature protection |
| CA2440582A1 (en) | 2001-03-09 | 2002-10-03 | Dyax Corp. | Serum albumin binding moieties |
| WO2003029462A1 (en) * | 2001-09-27 | 2003-04-10 | Pieris Proteolab Ag | Muteins of human neutrophil gelatinase-associated lipocalin and related proteins |
| EP1430136A1 (en) | 2001-09-27 | 2004-06-23 | Pieris ProteoLab AG | Muteins of apolipoprotein d |
| JP2006523226A (ja) | 2003-02-28 | 2006-10-12 | ザ ジョンズ ホプキンス ユニバーシティ | Ｔ細胞調節方法 |
| WO2005019255A1 (en) | 2003-08-25 | 2005-03-03 | Pieris Proteolab Ag | Muteins of tear lipocalin |
| EP2899277A1 (en) | 2004-11-26 | 2015-07-29 | Pieris AG | Compound with affinity for the cytotoxic T lymphocyte-associated antigen (CTLA-4) |
| US20070212703A1 (en) | 2005-09-27 | 2007-09-13 | Stemmer Willem P | Proteinaceous pharmaceuticals and uses thereof |
| EP1996613B1 (en) * | 2006-03-20 | 2014-04-30 | Technische Universität München | Muteins of tear lipocalin with affinity for the t-cell coreceptor cd4 |
| CA2713557C (en) | 2008-01-30 | 2016-06-07 | Pieris Ag | Muteins of tear lipocalin having affinity to human c-met receptor tyrosine kinase and methods for obtaining the same |
| SG10201604566QA (en) | 2011-12-13 | 2016-07-28 | Pieris Ag | Methods for preventing or treating certain disorders by inhibiting binding of il-4 and/or il-13 to their respective receptors |
| US9522940B2 (en) * | 2012-05-23 | 2016-12-20 | Pieris Pharmaceuticals Gmbh | Lipocalin muteins with binding-affinity for glypican-3 (GPC-3) and use of lipocalin muteins for target-specific delivery to cells expressing GPC-3 |
| CA2891557A1 (en) | 2013-03-26 | 2014-05-22 | Pieris Ag | Novel specific-binding polypeptides and uses thereof |
| AU2015205530B8 (en) * | 2014-01-13 | 2019-09-19 | Pieris Pharmaceuticals Gmbh | Multi-specific polypeptide useful for localized tumor immunomodulation |
| FI3298030T3 (fi) * | 2015-05-18 | 2023-02-22 | Pieris Pharmaceuticals Gmbh | Syöpää ehkäisevä fuusiopolypeptidi |
| CN108348573A (zh) | 2015-07-15 | 2018-07-31 | 皮里斯制药有限公司 | Lag-3特异性的新型蛋白 |
| MX2019008434A (es) | 2017-01-18 | 2019-11-11 | Pieris Pharmaceuticals Gmbh | Muteínas de lipocalina con afinidad de unión por lag-3. |
-
2018
- 2018-01-18 MX MX2019008434A patent/MX2019008434A/es unknown
- 2018-01-18 BR BR112019014691A patent/BR112019014691A2/pt not_active IP Right Cessation
- 2018-01-18 CN CN201880017771.8A patent/CN110402252A/zh active Pending
- 2018-01-18 EP EP18702146.4A patent/EP3571219A1/en not_active Withdrawn
- 2018-01-18 CA CA3050194A patent/CA3050194A1/en active Pending
- 2018-01-18 KR KR1020197023946A patent/KR20190104409A/ko not_active Ceased
- 2018-01-18 JP JP2019559395A patent/JP7225116B2/ja active Active
- 2018-01-18 AU AU2018209178A patent/AU2018209178B2/en not_active Ceased
- 2018-01-18 US US16/478,465 patent/US11168119B2/en not_active Expired - Fee Related
- 2018-01-18 RU RU2019122482A patent/RU2019122482A/ru not_active Application Discontinuation
- 2018-01-18 SG SG11201906509WA patent/SG11201906509WA/en unknown
- 2018-01-18 WO PCT/EP2018/051139 patent/WO2018134274A1/en not_active Ceased
-
2021
- 2021-10-12 US US17/499,640 patent/US11773147B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| AU2018209178A1 (en) | 2019-08-01 |
| EP3571219A1 (en) | 2019-11-27 |
| US11168119B2 (en) | 2021-11-09 |
| US20190345207A1 (en) | 2019-11-14 |
| KR20190104409A (ko) | 2019-09-09 |
| JP7225116B2 (ja) | 2023-02-20 |
| CA3050194A1 (en) | 2018-07-26 |
| US11773147B2 (en) | 2023-10-03 |
| CN110402252A (zh) | 2019-11-01 |
| BR112019014691A2 (pt) | 2020-04-07 |
| US20220098253A1 (en) | 2022-03-31 |
| WO2018134274A1 (en) | 2018-07-26 |
| AU2018209178B2 (en) | 2021-07-29 |
| JP2020505948A (ja) | 2020-02-27 |
| RU2019122482A (ru) | 2021-02-19 |
| RU2019122482A3 (enExample) | 2021-05-26 |
| SG11201906509WA (en) | 2019-08-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2018000447A (es) | Novedosas proteinas especificas para lag-3. | |
| PH12017501583A1 (en) | Novel proteins specific for cd137 | |
| MX2019008434A (es) | Muteínas de lipocalina con afinidad de unión por lag-3. | |
| PH12020500500A1 (en) | Pyrazolopyrimidinone compounds and uses thereof | |
| MX2025009223A (es) | Agentes de union a clec9a y su uso | |
| MX2018001567A (es) | Novedosos polipeptidos de fusion especificos para lag-3 y pd-1. | |
| MX2025008493A (es) | Agentes de union a fibroblastos y uso de estos | |
| SG10201906859PA (en) | Novel proteins specific for angiogenesis | |
| MX2020001996A (es) | Moleculas anti-cd137 y uso de estas. | |
| WO2018170338A3 (en) | High affinity mage-a1-specific tcrs and uses thereof | |
| PH12017501473A1 (en) | Novel proteins specific for pyoverdine and pyochelin | |
| WO2019006005A3 (en) | METHODS AND COMPOSITIONS FOR THE TREATMENT OF MELANOMA | |
| MY200710A (en) | Novel fusion protein specific for cd137 and pd-l1 | |
| EP4378962A3 (en) | Anti-cancer fusion polypeptide | |
| CA3013558C (en) | CD8 LIAISON OFFICERS | |
| MX2021010039A (es) | Novedosas proteinas de fusion especificas para cd137 y gpc3. | |
| PH12015501067A1 (en) | Pyrrolopyrimidine compounds as kinase inhibitors | |
| MX2024003743A (es) | Inmunoglobulinas de union a agrecano. | |
| MX2019003543A (es) | Anticuerpos que se fijan al interleucina-2 y sus usos. | |
| PH12022553153A1 (en) | Binding molecules for the treatment of cancer | |
| MX2020002585A (es) | Inhibidor de hdac combinado con un modulador del punto de control inmunitario para la terapia contra el cancer. | |
| MX2019014365A (es) | Tratamiento topico de la enfermedad intestinal inflamatoria usando anticuerpos y fragmentos de los mismos. | |
| MX2015009348A (es) | Composiciones hemostaticas. | |
| MX2021009189A (es) | Belantamab mafodotin en combinación con pembrolizumab para el tratamiento del cáncer. | |
| WO2023034923A3 (en) | BISPECIFIC AND TRISPECIFIC BINDING PROTEINS TO PD-L1, CD137, AND/OR TGFβ AND USES THEREOF |